[1] Katsarou A, Pantopoulos K.Basics and principles of cellular and systemic iron homeostasis[J].Mol Aspects Med,2020,75:100866.
[2] 陈春梅,葛品,郭翀. 人体铁代谢及其调控因素[J].基础医学与临床,2022,42(5):818-823.
[3] Hershko C, Graham G, Bates G W, et al.Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity[J].Br J Haematol,1978,40(2):255-263.
[4] Breuer W, Hershko C, Cabantchik Z I.The importance of non-transferrin bound iron in disorders of iron metabolism[J].Transfus Sci,2000,23(3):185-192.
[5] Brissot P, Cavey T, Ropert M, et al.Genetic hemochromatosis: Pathophysiology, diagnostic and therapeutic management[J].Presse Med,2017,46(12 Pt 2):e288-e295.
[6] Fibach E, Rachmilewitz E A.Iron overload in hematological disorders[J].Presse Med,2017,46(12 Pt 2):e296-e305.
[7] Hellstrom-Lindberg E.Management of anemia associated with myelodysplastic syndrome[J].Semin Hematol,2005,42(2 Suppl 1):S10-S13.
[8] Murphy C J, Oudit G Y.Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment[J].J Card Fail,2010,16(11):888-900.
[9] Li S, Zhang X.Iron in Cardiovascular Disease: Challenges and Potentials[J].Front Cardiovasc Med,2021,8:707138.
[10] Vinchi F, Porto G, Simmelbauer A, et al.Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction[J].Eur Heart J,2020,41(28):2681-2695.
[11] 杨育超,杨忠明,武雪,等. 铁超载诱导心肌细胞损伤机制的研究进展[J].吉林大学学报(医学版),2015,41(2):433-436.
[12] Crist B L, Alekel D L, Ritland L M, et al.Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women[J].J Womens Health (Larchmt),2009,18(6):795-801.
[13] Sun L, Franco O H, Hu F B, et al.Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese[J].J Clin Endocrinol Metab,2008,93(12):4690-4696.
[14] Turbino-Ribeiro S M, Silva M E, Chianca D J, et al. Iron overload in hypercholesterolemic rats affects iron homeostasis and serum lipids but not blood pressure[J].J Nutr,2003,133(1):15-20.
[15] Kiechl S, Willeit J, Egger G, et al.Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study[J].Circulation,1997,96(10):3300-3307.
[16] Duffy S J, Biegelsen E S, Holbrook M, et al.Iron chelation improves endothelial function in patients with coronary artery disease[J].Circulation,2001,103(23):2799-2804.
[17] Fernandez-Real J M, Penarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity[J].Diabetes Care,2002,25(12):2249-2255.
[18] Pratico D, Pasin M, Barry O P, et al.Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C[J].Circulation,1999,99(24):3118-3124.
[19] Day S M, Duquaine D, Mundada L V, et al.Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis[J].Circulation,2003,107(20):2601-2606.
[20] Menasche P, Grousset C, Gauduel Y, et al.Prevention of hydroxyl radical formation: a critical concept for improving cardioplegia. Protective effects of deferoxamine[J].Circulation,1987,76(5 Pt 2):V180-V185.
[21] Ishizaka N, Saito K, Mitani H, et al.Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation[J].Circulation,2002,106(14):1840-1846.
[22] Yu C M, Tipoe G L, Wing-Hon L K, et al. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction[J].J Am Coll Cardiol,2001,38(4):1207-1215.
[23] Harada K, Sugaya T, Murakami K, et al.Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction[J].Circulation,1999,100(20):2093-2099.
[24] Rosenthal E A, Bohlmeyer T J, Monnet E, et al.An iron-binding exochelin prevents restenosis due to coronary artery balloon injury in a porcine model[J].Circulation,2001,104(18):2222-2227.
[25] Daemen M J, Lombardi D M, Bosman F T, et al.Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall[J].Circ Res,1991,68(2):450-456.
[26] Runge M S, Molnar K, Madamanchi N R. "Old" hearts and arteries: the role of oxidative stress[J].Trans Am Clin Climatol Assoc,2010,121:52-58, 59-60.
[27] 刘洁,罗立波,颜晓静. 冠心病铁死亡发病机制及药物干预研究进展[J].中国现代医药杂志,2023,25(07):91-98.
[28] Oudit G Y, Trivieri M G, Khaper N, et al.Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy[J].J Mol Med (Berl),2006,84(5):349-364.
[29] Corna G, Galy B, Hentze M W, et al.IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice[J].J Mol Med (Berl),2006,84(7):551-560.
[30] Rose R A, Sellan M, Simpson J A, et al.Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation[J].Circ Arrhythm Electrophysiol,2011,4(5):733-742.
[31] Oudit G Y, Trivieri M G, Khaper N, et al.Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model[J].Circulation,2004,109(15):1877-1885.
[32] Klip I T, Comin-Colet J, Voors A A, et al.Iron deficiency in chronic heart failure: an international pooled analysis[J].Am Heart J,2013,165(4):575-582.
[33] Ozcan C, Palmeri M, Horvath T L, et al.Role of uncoupling protein 3 in ischemia-reperfusion injury, arrhythmias, and preconditioning[J].Am J Physiol Heart Circ Physiol,2013,304(9):H1192-H1200.
[34] Gao X, Qian M, Campian J L, et al.Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload[J].Free Radic Biol Med,2010,49(3):401-407.
[35] Goldhaber J I, Qayyum M S.Oxygen free radicals and excitation-contraction coupling[J].Antioxid Redox Signal,2000,2(1):55-64.
[36] Haskova P, Kovarikova P, Koubkova L, et al.Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity[J].Free Radic Biol Med,2011,50(4):537-549.
[37] Thandavarayan R A, Watanabe K, Ma M, et al.Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus[J].Am J Physiol Heart Circ Physiol,2009,297(3):H911-H919.
[38] Schwartz K A, Li Z, Schwartz D E, et al.Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction[J].J Appl Physiol (1985),2002,93(2):746-751.
[39] Bacon B R, Adams P C, Kowdley K V, et al.Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology,2011,54(1):328-343.
[40] Díez-López C, Comín-Colet J, González-Costello J.Iron overload cardiomyopathy[J].Current Opinion in Cardiology,2018,33(3):334-340.
[41] Radenkovic D, Weingartner S, Ricketts L, et al.T(1) mapping in cardiac MRI[J].Heart Fail Rev,2017,22(4):415-430.
[42] Wongjaikam S, Kumfu S, Chattipakorn S C, et al.Current and future treatment strategies for iron overload cardiomyopathy[J].European Journal of Pharmacology,2015,765:86-93.
[43] Hoffbrand A V, Taher A, Cappellini M D.How I treat transfusional iron overload[J].Blood,2012,120(18):3657-3669.
[44] Davis B A, Porter J B.Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia[J].Blood,2000,95(4):1229-1236.
[45] Taher A, Cappellini M D, Vichinsky E, et al.Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload[J].Br J Haematol,2009,147(5):752-759.
[46] Tanner M A, Galanello R, Dessi C, et al.A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance[J].Circulation,2007,115(14):1876-1884.
[47] Cheng C F, Lian W S.Prooxidant mechanisms in iron overload cardiomyopathy[J].Biomed Res Int,2013,2013:740573.
[48] Zhang J P, Zhang Y Y, Zhang Y, et al.Salvia miltiorrhiza (Danshen) injection ameliorates iron overload-induced cardiac damage in mice[J].Planta Med,2013,79(9):744-752. |
